Strategies for sensitivity enhancement of point-of-care devices

Roy, Lavanika; Buragohain, Pronamika; Borse, Vivek

doi:10.1016/j.biosx.2021.100098

Cited by 16 publications

(18 citation statements)

References 144 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanodiagnostic tools are advanced diagnostic devices developed by integrating nanotechnology with biomedical engineering. The development of nanotechnology-based diagnostic devices has revolutionized the medical field with the introduction of miniaturized diagnostics ( Borse et al, 2020a , 2020b , 2022 ; Borse and Srivastava, 2019 , 2020 ; Kaur et al, 2021 ; Konwar and Borse, 2020 ; Roy et al, 2022 ). Fig.…”

Section: Nanodiagnostic Techniques For Covid-19 Detectionmentioning

confidence: 99%

Outlook of various diagnostics and nanodiagnostic techniques for COVID-19

Preethi

Roy

Lahkar

et al. 2022

Biosensors and Bioelectronics: X

View full text Add to dashboard Cite

Section: Nanodiagnostic Techniques For Covid-19 Detectionmentioning

confidence: 99%

Outlook of various diagnostics and nanodiagnostic techniques for COVID-19

Preethi

Roy

Lahkar

et al. 2022

Biosensors and Bioelectronics: X

View full text Add to dashboard Cite

“…Such an increase may be achieved by crosslinking functionalized nanoparticles (conjugates), where the primary conjugate reacts with the antigen, and the secondary conjugate binds to the primary one, accumulating a high amount of the label per immunocomplex. This signal amplification strategy is utilized in various bioanalytical methods such as ELISA, immunohistochemistry, and biosensing [8, 9] . All these methods use consequent delivery of reagents and require multiple incubation and washing steps.…”

Section: Figurementioning

confidence: 99%

“…This signal amplification strategy is utilized in various bioanalytical methods such as ELISA, immunohistochemistry, and biosensing. [8,9] All these methods use consequent delivery of reagents and require multiple incubation and washing steps. Keeping LFIA within the paradigm of a method driven by capillary action makes this multi-step strategy inapplicable.…”

mentioning

confidence: 99%

Electrophoresis‐Assisted Multilayer Assembly of Nanoparticles for Sensitive Lateral Flow Immunoassay**

et al. 2022

View full text Add to dashboard Cite

Lateral flow immunoassay (LFIA) is a rapid, simple, and inexpensive point-of-need method. A major limitation of LFIA is a high limit of detection (LOD), which impacts its diagnostic sensitivity. To overcome this limitation, we introduce a signal-enhancement procedure that is performed after completing LFIA and involves controllably moving biotin-and streptavidinfunctionalized gold nanoparticles by electrophoresis. The nanoparticles link to immunocomplexes forming multilayer aggregates on the test strip, thus, enhancing the signal. Here, we demonstrate lowering the LOD of hepatitis B surface antigen from approximately 8 to 0.12 ng mL À 1 , making it clinically acceptable. Testing 118 clinical samples for hepatitis B showed that signal enhancement increased the diagnostic sensitivity of LFIA from 73 % to 98 % while not affecting its 95 % specificity. Electrophoresis-driven enhancement of LFIA is universal (antigen-independent), takes two minutes, and can be performed by an untrained person.

show abstract

“…PIC biosensors offer advantageous features such as a high analytical sensitivity, the capability for multiplexing and miniaturization, and the suitability for integration in optofluidic devices [ 28 , 29 ]. Additionally, these sensors offer advantages such as the prospect of label-free detection, the possibility of real-time measurement, immunity to electromagnetic interference, and the high potential for integration with other (micro) components.…”

Section: Introductionmentioning

confidence: 99%

Asymmetric Mach–Zehnder Interferometric Biosensing for Quantitative and Sensitive Multiplex Detection of Anti-SARS-CoV-2 Antibodies in Human Plasma

et al. 2022

View full text Add to dashboard Cite

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic has once more emphasized the urgent need for accurate and fast point-of-care (POC) diagnostics for outbreak control and prevention. The main challenge in the development of POC in vitro diagnostics (IVD) is to combine a short time to result with a high sensitivity, and to keep the testing cost-effective. In this respect, sensors based on photonic integrated circuits (PICs) may offer advantages as they have features such as a high analytical sensitivity, capability for multiplexing, ease of miniaturization, and the potential for high-volume manufacturing. One special type of PIC sensor is the asymmetric Mach–Zehnder Interferometer (aMZI), which is characterized by a high and tunable analytical sensitivity. The current work describes the application of an aMZI-based biosensor platform for sensitive and multiplex detection of anti-SARS-CoV-2 antibodies in human plasma samples using the spike protein (SP), the receptor-binding domain (RBD), and the nucleocapsid protein (NP) as target antigens. The results are in good agreement with several CE-IVD marked reference methods and demonstrate the potential of the aMZI biosensor technology for further development into a photonic IVD platform.

show abstract

Strategies for sensitivity enhancement of point-of-care devices

Cited by 16 publications

References 144 publications

Outlook of various diagnostics and nanodiagnostic techniques for COVID-19

Outlook of various diagnostics and nanodiagnostic techniques for COVID-19

Electrophoresis‐Assisted Multilayer Assembly of Nanoparticles for Sensitive Lateral Flow Immunoassay**

Asymmetric Mach–Zehnder Interferometric Biosensing for Quantitative and Sensitive Multiplex Detection of Anti-SARS-CoV-2 Antibodies in Human Plasma

Contact Info

Product

Resources

About